亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

丙戊酸鈉

 
 
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 山東濟(jì)南市付款后3天內(nèi)
品牌 惠誠(chéng)
過期 長(zhǎng)期有效
更新 2017-07-19 10:00
 

濟(jì)南惠誠(chéng)醫(yī)藥科技有限公司

企業(yè)會(huì)員第10年
資料未認(rèn)證
保證金未繳納
詳細(xì)說明

中文名稱: 丙戊酸鈉

中文同義詞: 2-丙基戊酸鈉;丙戊酸鈉;敵白痙;癲撲凈'定百痙'德巴金;二丙乙酸鈉;抗癲靈;抗癲癎;德巴金

英文名稱: Sodium 2-propylpentanoate

英文同義詞: 2-propyl-pentanoicacisodiumsalt;2-propylvalericacidsodiumsalt;2-propyl-valericacisodiumsalt;dipropylacetatesodium;eurekene;kw6066n;labazene;orfiril

CAS號(hào): 1069-66-5

分子式: C8H15NaO2

分子量: 166.19

EINECS號(hào): 213-961-8

相關(guān)類別: Valproic acid Series;丙戊酸系列;Intermediates & Fine Chemicals;Pharmaceuticals;GABA/Glycine receptor;Inhibitor;VANCOCIN;其他科研原料藥;醫(yī)藥中間體

用途:一種不含氮的廣譜抗癲癇藥,用于治療和預(yù)防各種類型癲癇,對(duì)失神性小發(fā)作、癲癇性行動(dòng)失常等療效更好

舉報(bào)收藏 0評(píng)論 0
更多>本企業(yè)其它產(chǎn)品
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |